Based on the aggregated intelligence of 180,000-plus investors participating in Motley Fool CAPS, the Fool's free investing community, biotech company Regeneron Pharmaceuticals
With that in mind, let's take a closer look at Regeneron's business and see what CAPS investors are saying about the stock right now.
Regeneron facts
| Headquarters (Founded) | Tarrytown, N.Y. (1988) |
| Market Cap | $9.9 billion |
| Industry | Biotechnology |
| Trailing-12-Month Revenue | $445.8 million |
| Management | Co-Founder/CEO Leonard Schleifer CFO Murray Goldberg |
| Return on Equity (Average, Past 3 Years) | (27.7%) |
| Cash/Debt | $810.6 million / $435.5 million |
| Competitors |
Amgen Novartis Roche Holding |
Sources: S&P Capital IQ and Motley Fool CAPS.
On CAPS, 27% of the 186 members who have rated Regeneron believe the stock will underperform the S&P 500 going forward.
Just a few of days ago, fellow Fool Sean Williams (TMFUltraLong) agreed with yours truly and questioned Regeneron's lofty valuation:
[F]antasyland valuation. There's no way that Eylea's forecast of $250 million-$300 million in sales translates into a $10.5 billion market cap. Avastin should give Eylea enough competition to bring Regeneron back to Earth. Never get too excited about new drugs otherwise you often get burned.
What do you think about Regeneron, or any other stock for that matter? If you want to retire rich, you need to protect your portfolio from any undue risk. Staying away from dangerous stocks is crucial to securing your financial future, and on Motley Fool CAPS, thousands of investors are working every day to flag them. CAPS is 100% free, so get started!
Want to see how well (or not so well) the stocks in this series are performing? Follow the new TrackPoisedTo CAPS account.
